Media

Amniotics is attending the 3rd Global bioprocessing, Bioanalytics & ATMP Manufacturing Congress 16-17 May 2022

News

May 16, 2022

Amniotics COO Jan Talts will be chairing two sessions at the 3RD GLOBAL BIOPROCESSING, BIOANALYTICS & ATMP MANUFACTURING CONGRESS taking place in Dublin the 16-17 of May 2022.

The titles of the sessions are “Quality control and regulatory landscape” and “Manufacturing cell & gene therapies”.
 
The sessions are taking place on Monday May 16, at 13:30 – 14:30 UTC/GMT +1 hour and Tuesday May 17, 10.10-10.40 UTC/GMT +1 hour).
https://www.global-engage.com/event/bioprocessing-bioanalytics/#speakers

About Amniotics

Amniotics is a biopharma company focusing on mesenchymal stem cells (MSC) from amniotic fluid. The company was born out of the discovery of a novel source of stem cells in full-term amniotic fluid. Based on a decade of research at the internationally recognized Lund University Stem Cell Centre and the Skåne University Hospital of Lund, the company is pioneering the harvesting and propagation of tissue specific neonatal quality mesenchymal stem cells (MSC). These stem cells have unique properties for applications in regenerative medicine. Amniotics has also an, by Läkemedelsverket (Swedish MPA), approved Good Manufacturing Practice (GMP) facility to produce Advanced Therapy Medicinal Products (ATMPs). With the GMP facilities operational since 2020, Amniotics is now moving into clinical trials with the leading drug candidate, PulmoStem™ and is looking to establish strategic partnerships with researchers and companies that are interested in developing stem-cell-based therapies targeting diseases with high unmet needs.

Amniotics (publ) has it´s headquarter in Lund, Sweden.

Amniotics Certified Adviser on First North is Redeye AB, certifiedadviser@redeye.se, telephone: +46 (0) 8 121 576 90.

The company is listed at Nasdaq First North Growth Market in Stockholm.

Learn more at www.amniotics.com. 

This press release is a translation of the Swedish original. In the event of any discrepancy between this translation and the Swedish original, the Swedish version shall prevail.

Upcoming events

Read more

Subscribe